12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Wellbutrin XL bupropion regulatory update

Valeant disclosed on its conference call to discuss 3Q12 earnings that it submitted a Citizen's Petition to FDA arguing that all generic versions of antidepressant 300 mg Wellbutrin XL bupropion should not be marketed until bioequivalence is demonstrated to "assure that...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >